Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Eflornithine - IWILFIN
Product / population
Adult and pediatric high-risk neuroblastoma indication; oral tablets. BSA and renal-function assessment are distinct inputs.
Renal method
Label prints eGFR <30 mL/min without indexing clarification; dosage bands use BSA in m2.
Source revision
Prescribing information revised 11/2024.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
IWILFIN: use the published renal BSA table, not automatic per-dose halving
The official table includes an asymmetric morning/evening band. Its tablet schedule is stored as published rather than generated by dividing each usual administration.
What to reconcile: Confirm BSA band and source renal units; apply the table rather than a percentage alone.
DailyMed / USWM, LLC · Adult and pediatric high-risk neuroblastoma indication; oral tablets. BSA and renal-function assessment are distinct inputs.
Renal method: Label prints eGFR <30 mL/min without indexing clarification; dosage bands use BSA in m2. Source date: Prescribing information revised 11/2024. Retrieved: 2026-09-08
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For severe impairment (eGFR <30), section 2.3 Table 2 specifies these oral regimens by BSA in m2:
BSA (m2)
Oral dose for eGFR <30 (source units: mL/min)
>1.5
384 mg twice daily
0.75 to 1.5
384 mg in the morning and 192 mg in the evening
0.5 to <0.75
192 mg twice daily
0.25 to <0.5
192 mg once daily
No regimen below BSA 0.25 is supplied in this table. Moderate impairment warrants close monitoring for liver toxicity, myelosuppression and hearing loss.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.